0QNA.LSE Basilea Pharmaceutica AG

Healthcare Commercial Services & Supplies London Exchange
52.59 GBP
Close of Aug 22, 2026
44.70 74.30
Market cap
GBP 572M
P/E
-
P/B
-
ROE
68.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 0QNA.LSE undervalued?

Graham number

The Graham number of Basilea Pharmaceutica AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Basilea Pharmaceutica AG fundamental analysis

No fundamental analysis for Basilea Pharmaceutica AG yet.

Basilea Pharmaceutica AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumo…

Full company profile